In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Guidance programme 2 selected

Guidance programme

Showing 1 to 10 of 14

TitleConsultationTypeConsultation end date
Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]Draft guidanceTechnology appraisal guidance
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Final draft guidanceTechnology appraisal guidance
Secukinumab for treating relapsed polymyalgia rheumatica ID6599Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable [ID6596]Draft guidanceTechnology appraisal guidance
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]Draft guidanceTechnology appraisal guidance
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]Final draft guidanceTechnology appraisal guidance
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]Final draft guidanceTechnology appraisal guidance
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All